COVID-19

Learnings from the COVID-19 pandemic for the advanced therapies sector 2:04
Learnings from the COVID-19 pandemic for the advanced therapies sector
Miguel Forte • 5 Oct 2021
Driving the development of gene therapies for more common conditions 3:00
Driving the development of gene therapies for more common conditions
Paul Gissen • 6 Oct 2021
Promising avenues in extracellular vesicle-based therapeutics 5:05
Promising avenues in extracellular vesicle-based therapeutics
Eva Rohde • 10 Jun 2021
Tackling unproven cell-based therapies and the impact of COVID-19 7:29
Tackling unproven cell-based therapies and the impact of COVID-19
Aaron Levine • 28 May 2021
The potential of oncolytic adenoviral vectors 1:32
The potential of oncolytic adenoviral vectors
Margarita Romanenko • 13 May 2021
AVA-Trap blood filtration for cytokine storm in COVID-19 6:26
AVA-Trap blood filtration for cytokine storm in COVID-19
Shuguang Zhang • 17 Jun 2021
What can CGT manufacturing learn from the COVID-19 pandemic? 6:15
What can CGT manufacturing learn from the COVID-19 pandemic?
Delara Motlagh • 1 Jun 2021
The state of investment in cell & gene therapy 3:31
The state of investment in cell & gene therapy
Matthew Durdy • 9 Apr 2021
What can the field learn from the COVID-19 pandemic? 2:45
What can the field learn from the COVID-19 pandemic?
Amy DuRoss • 8 Apr 2021
The lasting impact of COVID-19 on the CGT sector 3:10
The lasting impact of COVID-19 on the CGT sector
Stephen Ward • 14 Apr 2021
Off-the-shelf cell therapy for bone indications: ALLOB & JTA-004 4:54
Off-the-shelf cell therapy for bone indications: ALLOB & JTA-004
Miguel Forte • 26 May 2021
Anticipating a crackdown on unproven cell-based therapies 4:09
Anticipating a crackdown on unproven cell-based therapies
Laertis Ikonomou • 25 May 2021
Exosomes: a game changer in mRNA-based therapeutics? 1:19
Exosomes: a game changer in mRNA-based therapeutics?
Linda Marban • 19 May 2021
Exosome-based mRNA vaccines against SARS-CoV-2 2:07
Exosome-based mRNA vaccines against SARS-CoV-2
Linda Marban • 19 May 2021
The impact of COVID-19 on validating cell therapy products 1:40
The impact of COVID-19 on validating cell therapy products
Bruce Levine • 11 Mar 2021
What to expect at ISCT 2021 1:50
What to expect at ISCT 2021
Bruce Levine • 11 Mar 2021
The content of VJRegenMed is intended for healthcare professionals